BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Down 4.5% - Time to Sell?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report)'s stock price dropped 4.5% during mid-day trading on Monday . The stock traded as low as $8.93 and last traded at $8.94. Approximately 3,088,508 shares were traded during mid-day trading, an increase of 2% from the average daily volume of 3,020,998 shares. The stock had previously closed at $9.36.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. HC Wainwright reiterated a "buy" rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 6th. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $13.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Monday. Cantor Fitzgerald started coverage on shares of BioCryst Pharmaceuticals in a research note on Tuesday, April 29th. They issued an "overweight" rating and a $20.00 target price on the stock. Wedbush raised their target price on shares of BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the stock an "outperform" rating in a report on Monday. Finally, Barclays upped their price target on shares of BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the company an "equal weight" rating in a report on Wednesday, May 7th. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $16.70.

BioCryst Pharmaceuticals Stock Performance

The stock's 50 day simple moving average is $10.03 and its 200 day simple moving average is $8.58. The firm has a market capitalization of $1.87 billion, a P/E ratio of -34.40, a P/E/G ratio of 2.68 and a beta of 1.04.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Allianz Asset Management GmbH increased its stake in shares of BioCryst Pharmaceuticals by 9.6% during the first quarter. Allianz Asset Management GmbH now owns 13,700 shares of the biotechnology company's stock valued at $103,000 after buying an additional 1,200 shares during the period. Xponance Inc. increased its position in BioCryst Pharmaceuticals by 9.1% during the 4th quarter. Xponance Inc. now owns 14,896 shares of the biotechnology company's stock valued at $112,000 after purchasing an additional 1,242 shares during the period. Royal Bank of Canada raised its holdings in shares of BioCryst Pharmaceuticals by 2.4% in the 1st quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company's stock valued at $476,000 after purchasing an additional 1,458 shares in the last quarter. Sei Investments Co. raised its holdings in shares of BioCryst Pharmaceuticals by 2.8% in the 4th quarter. Sei Investments Co. now owns 57,190 shares of the biotechnology company's stock valued at $430,000 after purchasing an additional 1,537 shares in the last quarter. Finally, SG Americas Securities LLC boosted its stake in shares of BioCryst Pharmaceuticals by 5.2% during the first quarter. SG Americas Securities LLC now owns 43,496 shares of the biotechnology company's stock valued at $326,000 after purchasing an additional 2,146 shares in the last quarter. 85.88% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.